[1]
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb:141(2 Suppl):e419S-e496S. doi: 10.1378/chest.11-2301. Epub
[PubMed PMID: 22315268]
Level 1 (high-level) evidence
[2]
You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GYH. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb:141(2 Suppl):e531S-e575S. doi: 10.1378/chest.11-2304. Epub
[PubMed PMID: 22315271]
Level 1 (high-level) evidence
[3]
Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, Sonnenberg FA, Schulman S, Vandvik PO, Spencer FA, Alonso-Coello P, Guyatt GH, Akl EA. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb:141(2 Suppl):e601S-e636S. doi: 10.1378/chest.11-2302. Epub
[PubMed PMID: 22315273]
Level 1 (high-level) evidence
[4]
Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb:141(2 Suppl):e576S-e600S. doi: 10.1378/chest.11-2305. Epub
[PubMed PMID: 22315272]
Level 1 (high-level) evidence
[5]
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb:141(2 Suppl):e44S-e88S. doi: 10.1378/chest.11-2292. Epub
[PubMed PMID: 22315269]
Level 1 (high-level) evidence
[6]
Di Minno A, Frigerio B, Spadarella G, Ravani A, Sansaro D, Amato M, Kitzmiller JP, Pepi M, Tremoli E, Baldassarre D. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood reviews. 2017 Jul:31(4):193-203. doi: 10.1016/j.blre.2017.02.001. Epub 2017 Feb 5
[PubMed PMID: 28196633]
[7]
Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb:141(2 Suppl):e152S-e184S. doi: 10.1378/chest.11-2295. Epub
[PubMed PMID: 22315259]
Level 1 (high-level) evidence
[8]
Bae GH, Nambudiri VE, Bach DQ, Danziger J, Faulkner-Jones B, McMahon C, Huang SJ. Rapidly progressive nonuremic calciphylaxis in the setting of warfarin. The American journal of medicine. 2015 Oct:128(10):e19-21. doi: 10.1016/j.amjmed.2015.05.049. Epub 2015 Jul 8
[PubMed PMID: 26164564]
[9]
Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Hematology. American Society of Hematology. Education Program. 2018 Nov 30:2018(1):339-347. doi: 10.1182/asheducation-2018.1.339. Epub
[PubMed PMID: 30504330]
[10]
Onysko M, Holcomb N, Hornecker J. Antibiotic interactions: Answers to 4 common questions. The Journal of family practice. 2016 Jul:65(7):442-8
[PubMed PMID: 27565097]
[11]
Edwin SB, Jennings DL, Kalus JS. An evaluation of the early pharmacodynamic response after simultaneous initiation of warfarin and amiodarone. Journal of clinical pharmacology. 2010 Jun:50(6):693-8. doi: 10.1177/0091270009351885. Epub 2010 Jan 15
[PubMed PMID: 20081064]
[12]
Lu Y, Won KA, Nelson BJ, Qi D, Rausch DJ, Asinger RW. Characteristics of the amiodarone-warfarin interaction during long-term follow-up. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2008 May 15:65(10):947-52. doi: 10.2146/ajhp060415. Epub
[PubMed PMID: 18463344]
Level 2 (mid-level) evidence
[13]
Tomisti L, Del Re M, Bartalena L, Tanda ML, Pucci A, Pambianco F, Danesi R, Braverman LE, Martino E, Bogazzi F. Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2013 Nov-Dec:19(6):1043-9. doi: 10.4158/EP13093.RA. Epub
[PubMed PMID: 23807523]
[14]
Bucerius J, Joe AY, Palmedo H, Reinhardt MJ, Biersack HJ. Impact of short-term hypothyroidism on systemic anticoagulation in patients with thyroid cancer and coumarin therapy. Thyroid : official journal of the American Thyroid Association. 2006 Apr:16(4):369-74
[PubMed PMID: 16646683]
[15]
Leonard CE, Brensinger CM, Bilker WB, Kimmel SE, Han X, Nam YH, Gagne JJ, Mangaali MJ, Hennessy S. Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. International journal of cardiology. 2017 Feb 1:228():761-770. doi: 10.1016/j.ijcard.2016.11.245. Epub 2016 Nov 12
[PubMed PMID: 27888753]
[16]
Weathermon R, Crabb DW. Alcohol and medication interactions. Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism. 1999:23(1):40-54
[PubMed PMID: 10890797]
[17]
Leite PM, Martins MAP, Castilho RO. Review on mechanisms and interactions in concomitant use of herbs and warfarin therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016 Oct:83():14-21. doi: 10.1016/j.biopha.2016.06.012. Epub 2016 Jun 17
[PubMed PMID: 27470545]
[18]
Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy. 2007 Sep:27(9):1237-47
[PubMed PMID: 17723077]
[19]
Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial. Annals of internal medicine. 2004 Jul 6:141(1):23-7
[PubMed PMID: 15238367]
Level 1 (high-level) evidence
[20]
Werba JP, Misaka S, Giroli MG, Yamada S, Cavalca V, Kawabe K, Squellerio I, Laguzzi F, Onoue S, Veglia F, Myasoedova V, Takeuchi K, Adachi E, Inui N, Tremoli E, Watanabe H. Overview of green tea interaction with cardiovascular drugs. Current pharmaceutical design. 2015:21(9):1213-9
[PubMed PMID: 25312732]
Level 3 (low-level) evidence
[21]
Werba JP, Misaka S, Giroli MG, Shimomura K, Amato M, Simonelli N, Vigo L, Tremoli E. Update of green tea interactions with cardiovascular drugs and putative mechanisms. Journal of food and drug analysis. 2018 Apr:26(2S):S72-S77. doi: 10.1016/j.jfda.2018.01.008. Epub 2018 Feb 14
[PubMed PMID: 29703388]
[22]
R Sousa A, Barreira R, Santos E. Low-dose warfarin maternal anticoagulation and fetal warfarin syndrome. BMJ case reports. 2018 Apr 7:2018():. pii: bcr-2017-223159. doi: 10.1136/bcr-2017-223159. Epub 2018 Apr 7
[PubMed PMID: 29627779]
Level 3 (low-level) evidence
[23]
Ferreira JL, Wipf JE. Pharmacologic Therapies in Anticoagulation. The Medical clinics of North America. 2016 Jul:100(4):695-718. doi: 10.1016/j.mcna.2016.03.007. Epub
[PubMed PMID: 27235611]
[24]
Yates SG, Sarode R. New strategies for effective treatment of vitamin K antagonist-associated bleeding. Journal of thrombosis and haemostasis : JTH. 2015 Jun:13 Suppl 1():S180-6. doi: 10.1111/jth.12970. Epub
[PubMed PMID: 26149021]
[25]
Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Archives of internal medicine. 2006 Feb 27:166(4):391-7
[PubMed PMID: 16505257]
Level 1 (high-level) evidence